Monday, November 9, 2026

Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia

NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Graviton BioScience today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to GV101, the Company's clinical-stage, potent and selective oral Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, for the treatment of Friedreich's ataxia (FA).

GV101 is one of Graviton's proprietary, investigational oral selective ROCK2 inhibitors. ROCK2 inhibition is a novel mechanism for FA therapy that targets the root genetic cause of the disease by increasing both frataxin transcription and translation. This genetic restoration alleviates mitochondrial dysfunction and cellular stress in cardiovascular and neurological tissues. Furthermore, ROCK2 inhibition has been shown to offer neuroprotection, promoting axonal regeneration and increasing neuronal survival. Promising preclinical studies have demonstrated that GV101 increases frataxin mRNA and protein levels, providing a potentially disease-modifying therapeutic approach to Friedreich's ataxia.